Skip to main content

Table 1 Baseline clinical trial characteristics

From: Discrepancies in endpoints between clinical trial protocols and clinical trial registration in randomized trials in oncology

 

Variables

Number of trials

(%)

Phase

II

10

(14)

III

57

(80)

Unspecified

4

(6)

Type of Tumor

Breast

13

(18)

Genitourinary

10

(14)

Gastrointestinal

6

(8)

Lung

10

(14)

Other solid tumors

14

(20)

Hematological

12

(17)

Any cancer

6

(8)

Publication

JCO

52

(73)

NEJM

17

(24)

Lancet

2

(3)

Registry

Clinicaltrials.gov

62

(87)

ISRCT

5

(7)

EudraCT

2

(3)

ANZCTR

1

(1)

NTR

1

(1)

Type of Intervention

Chemotherapy

22

(31)

Targeted therapy

26

(37)

Chemotherapy and radiation

6

(8)

Surgery or radiation

6

(8)

Supportive care

11

(15)

Trial Initiation Period

1994–2005

30

(42)

2006–2010

41

(58)

Trial Result

Negative

37

(52)

Positive

34

(48)

Funding Source

Non-pharma

33

(46)

Pharma

38

(54)

Length of Trial

<  3 years

30

(42)

≥  3 years

41

(58)

Protocols with endpoints

Primary endpoints

71

(100)

Secondary endpoints

71

(100)

Exploratory endpoints

28

(39)

  1. Abbreviations: JCO Journal of Clinical Oncology, NEJM New England Journal of Medicine, ISRCT International Standard Randomized Control Trial, EudraCT European Clinical Trials Database, ANZCTR Australian New Zealand Clinical Trial Registry, NTR Netherlands National Trial Register